Athira Pharma, Inc/$ATHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Athira Pharma, Inc
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Ticker
$ATHA
Sector
Primary listing
Employees
-
Headquarters
Website
ATHA Metrics
BasicAdvanced
$15M
-
-$15.41
3.02
-
Price and volume
Market cap
$15M
Beta
3.02
52-week high
$4.59
52-week low
$3.66
Financial strength
Current ratio
10.808
Quick ratio
10.004
Long term debt to equity
1.807
Total debt to equity
3.18
Profitability
EBITDA (TTM)
-56.915
Management effectiveness
Return on assets (TTM)
-49.29%
Return on equity (TTM)
-103.80%
Valuation
Price to book
0.47
Price to tangible book (TTM)
0.47
Price to free cash flow (TTM)
-0.209
Free cash flow yield (TTM)
-479.04%
Free cash flow per share (TTM)
-18.203
Growth
Earnings per share change (TTM)
-48.09%
3-year earnings per share growth (CAGR)
-9.26%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Athira Pharma, Inc stock?
Athira Pharma, Inc (ATHA) has a market cap of $15M as of October 14, 2025.
What is the P/E ratio for Athira Pharma, Inc stock?
The price to earnings (P/E) ratio for Athira Pharma, Inc (ATHA) stock is 0 as of October 14, 2025.
Does Athira Pharma, Inc stock pay dividends?
No, Athira Pharma, Inc (ATHA) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Athira Pharma, Inc dividend payment date?
Athira Pharma, Inc (ATHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Athira Pharma, Inc?
Athira Pharma, Inc (ATHA) has a beta rating of 3.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.